A 20-week, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Safety and Efficacy of HM11260C on Body Weight in Obese Subjects Without Diabetes is a PHASE2 clinical asset sponsored by Hanmi Pharmaceutical Company Limited in Obesity. SEO and diligence focus: HM11260C, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.